CC-3052: A water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-α production

Journal of Immunology

Volumn 161, Issue 8, 1998, Pages 4236-4243

  Marriott, J Blake ^a   Westby, Michael ^a,c   Cookson, Sharon ^a   Guckian, Mary ^a   Goodbourn, Steve ^a   Muller, George ^b   Shire, Mary G ^b   Stirling, David ^b   Dalgleish, Angus G ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b CELGENE CORPORATION   (United States)

^c ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CC 3052; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; PHOSPHODIESTERASE IV; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CYTOKINE PRODUCTION; DRUG SOLUBILITY; DRUG STABILITY; EMBRYO; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOMODULATION; MUTAGENICITY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RAT; TERATOGENICITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES, MONONUCLEAR; MICE; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032531993     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Marriott, J. B., M. Westby, and A. G. Dalgleish. 1997. The therapeutic potential of TNF-α inhibitors old and new. Drug Discov. Today 2:273.
2. Dezube, B. J., J. L. Fridovich-Keil, R. F. Lange, and A. B. Pardee. 1990. Pentoxifylline and wellbeing in patients with cancer. Lancet 335:662.
3. Sampaio, E. P., G. Kaplan, A. Miranda, J. A. Nery, C. P. Miguel, S. M. Viana, and E. N. Sarno. 1993. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J. Infect. Dis. 168:408.
4. Elliott, M. J., R. N. Maini, M. Feldmann, J. R. Kalden, C. Antoni, J. S. Smolen, B. Leeb, F. C. Breedveld, J. D. Macfarlane, H. Bill, et al. 1994. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105.
5. Van Dullemen, H. M., S. J. Van Deventer, D. W. Hommes, H. A. Bijl, J. Jansen, G. N. Tytgat, and J. Woody. 1995. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109:129.
6. Sampaio, E. P., E. N. Sarno, R. Galilly, Z. A. Cohn, and G. Kaplan. 1991. Thalidomide selectively inhibits tumour necrosis factor α production by stimulated human monocytes. J. Exp. Med. 173:699.
7. Schuler, U., and G. Ehninger. 1995. Thalidomide: rationale for renewed use in immunological disorders. Drug Safety 12:364.
8. Youle, M., J. Clarbour, C. Furthing, M. Connolly, D. Hawkins, R. Staughton and B. Gazzard. 1989. Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. Br. Med. J. 298:432.
9. Jacobson, J. M., J. S. Greenspan, J. Spritzler, N. Ketter, J. L. Fahey, J. B. Jackson, L. Fox, M. Chernoff, A. W. Wu, L. A. MacPhail, G. J. Vasquez, and D. A. Wohl. 1997. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N. Engl. J. Med. 336:1487.
10. Klausner, J. D., S. Makonkawkeyoon, P. Akarasewi, K. Nakata, W. Kasinrerk, L. Corral, R. L. Dewar, H. C. Lane, V. H. Freedman, and G. Kaplan. 1996. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J. Acquired Immune Defic. Syndr. 11:247.
11. Vogelsang, G. B., E. R. Farmer, A. D. Hess, V. Altamonte, W. E. Beschorner, D. A. Jabs, R. L. Corio, L. S. Levin, O. M. Colvin, J. R. Wingard, et al. 1992. Thalidomide for the treatment of chronic graft-versus-host disease. N. Engl. J. Med. 326:1055.
12. Sharpstone, D., A. Rowbottom, M. Nelson, and B. Gazzard. 1995. The treatment of microsporidial diarrhoea with thalidomide. AIDS 9:658.
13. Reyes-Teràn G., J. G. Sierra-Madero, V. Martinez Del Cerro, H. Arroyo-Figueroa, A. Pasquetti, J. J. Calva, and G. M. Ruiz-Palacios. 1996. Effects of thalidomide on HIV-associated wasting syndrome: a randomized double-blind, placebo-controlled clinical trial. AIDS 10:1501.
14. Muller, G. W., L. G. Corral, M. G. Shire, H. Wang, A. Moreira, G. Kaplan, and D. I. Stirling. 1996. Structural modifications of thalidomide produce analogs with enhanced tumour necrosis factor inhibitory activity. J. Med. Chem. 39:3238.
15. Shattock, R. J., J. S. Friedland, and G. E. Griffin. 1993. Release of human immunodeficiency virus by THP-1 cells and human macrophages is regulated by cellular adherence and activation. J. Virol. 67:3569.
16. Whiteside, S. T., K. V. Visvanathan, and S. Goodbourn. 1992. Identification of novel factors that bind to the PRD I region of the human beta-interferon promoter. Nucleic Acids Res. 20:1531.
17. Visvanathan, K. V., and S. Goodbourn. 1989. Double-stranded RNA activates binding of NF-κ B to an inducible element in the human beta-interferon promoter. Embo J. 8:1129.
18. Hill, P. A., and R. L. Mitchell. 1994. Characterisation of phosphodiesterase activity from U937 cells. Faseb J. 8:A217.
19. Di Santo, M. E., and R. J. Heaslip. 1993. Identification and stabilization of large molecular weight PDE-IVs from U397 cells. Biochem. Biophys. Res. Commun. 197:1126.
20. Flint, O. P. 1987. An in vitro test for teratogens using cultures of rat embryo cells. In In Vitro Methods in Toxicology. C. K. Aterwill and C. E. Steele, eds. Cambridge University Press, Cambridge, U.K. pp. 339-363.
21. Babich, H., and E. Borenfreund. 1990. Cytotoxic effects of food additives and pharmaceuticals on cells in culture as determined with the neutral red assay. J. Pharmacol. Sci. 79:592.
22. Marriott, J. B., S. Cookson, E. Carlin, M. Youle, D. A. Hawkins, M. Nelson, M. Pearson, A. N. Vaughan, B. Gazzard, and A. G. Dalgleish. 1997. A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: clinical tolerance and effect on activation markers and cytokines. AIDS Res. Hum. Retroviruses 13:1625.
23. Sooville, C. D. 1996. Results of the extension phase of the open trial of thalidomide in the treatment of rheumatoid arthritis. Arthritis Rheum. 39:S281 (Abstract No. 1523).
24. Lee, S., J. Klausner, S. Oliver, G. Kaplan, and E. McCullagh. 1996. Treatment of rheumatoid arthritis with thalidomide. Arthritis Rheum. 39:S282 (Abstract No. 1524).
25. Platzer, C., C. Meisel, K. Vogt, M. Platzer, and H. D. Volk. 1995. Up-regulation of monocytic IL-10 by tumor necrosis factor-α and cAMP elevating drugs. Int. Immunol. 7:517.
26. Wanidworanum, C., and W. Strober. 1993. Predominant role of tumor necrosis factor-α in monocyte IL-10 synthesis J. Immunol. 151:6853.
27. Shaw, G., and R. Kamen. 1986. A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 46:459.
28. Moreira, A. L., E. P. Sampaio, A. Zmudzinas, P. Frindt, K. A. Smith, and G. Kaplan. 1993. Thalidomide exerts its inhibitory action on tumour necrosis factor α by enhancing mRNA degradation. J. Exp. Med. 177:1675.
29. Moreira, A. L., L. G. Corral, W. G. Ye, B. Johnson, D. Stirling, G. W. Muller, V. W. Freedman, and G. Kaplan. 1997. AIDS Res. Hum. Retroviruses 13:857.
30. Corral, L. G., G. W. Muller, A. L. Moreira, Y. Chen, M. Wu, D. Stirling, and G. Kaplan. 1996. Selection of novel analogs of thalidomide with enhanced tumour necrosis factor α inhibitory activity. Mol. Med. 2:506.